Hoppa till innehållet

OMXSPI-0,44%

S&P 500+0,02%

FTSE 100-0,76%

DAX-0,52%

NIKKEI-0,17%
AcouSort extends collaboration with leading cell therapy company into a third project phase

AcouSort’s collaboration with the global life science company has reached yet another significant milestone with the signing of a Statement of Work (SoW) describing Phase 3 in the ongoing collaboration. The new assignment will generate revenues of at least SEK 485,000 in 2024.

The collaboration, which began in 2022, aims to demonstrate how AcouSort’s AcouWash technology can be adapted for industrial use and integrated as OEM components to automate certain processing steps in the partnering company’s future cell therapy products and instruments. The feedback from the partnering company has been positive throughout the collaboration and in the now agreed phase 3, AcouSort will optimize and expand its technology so that it can be used in all relevant steps of cell therapy production processes.

“With the positive feedback we have received throughout the collaboration, the signing of the SoW comes as no surprise, but is still extremely gratifying. AcouSort will now take another step forwards within this strategically important partnership with the ambition to ultimately establish profitable sales of disposable OEM components. We could not have wished for a better start to the year,” says Torsten Freltoft, AcouSort’s CEO.

This information is information that AcouSort is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-01-18 14:00 CET.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments
AcouSort extends collaboration with leading cell therapy company into a third project phase

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera